Targeting MALT1 in B-cell Lymphomas

Related Experiment Video

Updated: Oct 31, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Huan-Chang Liang1, Kojo S J Elenitoba-Johnson1

  • 1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Blood Cancer Discovery
|October 30, 2026
PubMed

Abstract:

Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas. See related article by Philippar et al., p. XX See related article by Hertzberg et al., p. XX.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: Oct 31, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities.

Cancer discovery·2026

The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis.

Cancer discovery·2025

FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells.

Blood advances·2022

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Leukemia·2022

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.

Leukemia·2022

BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.

Cancer discovery·2022

Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma.

Blood cancer discovery·2026

Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use.

Blood cancer discovery·2026

CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All.

Blood cancer discovery·2026

A (Post)translational Opportunity in RAS-Dependent Heme Malignancy.

Blood cancer discovery·2026

Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.

Blood cancer discovery·2026

A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.

Blood cancer discovery·2026

From Dysfunction to Differentiation: A New Paradigm of T Cell Exhaustion.

Acta naturae·2026

Additional B-Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real-World Retrospective Observational Single-Center Cohort Study.

MedComm·2026

Targeting BIGH3 in selected solid tumors through a pH-Dependent antibody engineering strategy.

Biochemistry and biophysics reports·2026

Correction: Solving the mystery of persistent isolated aspartate aminotransferase elevation: Macro-AST as a decisive diagnostic consideration.

Frontiers in cellular and infection microbiology·2026

Calcineurin Inhibitor-Free, mTOR-Based Immunosuppression in Chimeric Antigen Receptor T-Cell Therapy for Post-Transplant Lymphoproliferative Disorder.

EJHaem·2026

Efficacy of teprotumumab N01 (IBI311), an IGF-1R inhibitor, for thyroid eye disease patients who had failed glucocorticoids.

International journal of ophthalmology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us